If the government is sincere about boosting the biotechnology sector, it needs to cut the red tape stifling development, industry insiders said yesterday.
"Taiwan's government requires new drugs, even locally developed ones, to obtain approval from at least one other country before applying for domestic permission," said Chen Kuang-chi (
"Such a requirement seems to indicate that the government lacks confidence in domestically developed pharmaceutical products," Chen said.
Maywufa Bio-Pharmaceutical is a Taipei-based company with businesses covering pharmaceutical research and development, drug distribution and drugstore chains. Its revenues reached NT$3.5 billion last year.
Chen said the industry hopes the regulatory authorities will abolish such unreasonable regulations for the sake of nurturing the nation's developing biotech industry.
The government said in 2002 that it would spare no efforts to promote the biotech industry, making it one of the key sectors of the government's "Two Trillion, Two Star" (兩兆雙星) investment plan for the next 10 years. Other sectors include semiconductors, flat-panel displays and digital content industries.
Annual revenues in the fledgling biotech industry rose 13 percent to NT$125.6 billion last year from NT$110.9 billion the previous year, according to figures provided by the Biotechnology & Pharmaceutical Industries Program Office (BPIPO) under the Ministry of Economic Affairs.
The government plans to pour NT$150 billion into the sector by 2006, hoping the investment can help boost annual revenues 25 percent a year to NT$250 billion by 2006, said William Chung (
Taiwan is one of several Asian countries where international biotech companies are considering possible business opportunities.
"Asia, with a population of 3.23 billion, is a market of huge potential for the industry," said Jonathan Watters, senior vice president of BioPro Pharmaceutical Inc, a Waikanae, New Zealand-based pharmaceutical R&D and marketing company.
Asia's market, excluding Japan, could be worth US$30 billion next year, with China making up 34 percent of the total, Watters said, and Taiwan 14 percent.
However, the variation in regulations between countries in the region make it more costly for companies to get drugs approved.
"One decision [for new drugs] can then become effective in 23 countries in the European Union, starting from this July," Watters said.
The industry, he added, was hoping Asian countries could harmonize regulatory requirements or recognize drugs approved elsewhere.
This is unlikely, even in the next few decades, as such a move would reduce countries' autonomy, said Chen Chei-hsiang (陳啟祥), director of BPIPO.
In the absence of regulatory harmonization, companies could encourage mutual recognition of their drugs by undertaking clinical trials for new drugs, a necessary process ahead of application, in several countries at the same time, Maywufa's Chen said.
"The result of scientific experiments would speak for us," Chen said. "And we expect cross-border efforts by the private sector to stimulate change in the official sector."
Elon Musk’s lieutenants have reached out to chip industry suppliers, including Applied Materials Inc, Tokyo Electron Ltd and Lam Research Corp, for his envisioned Terafab, early steps in an audacious and likely arduous attempt to break into the production of cutting-edge chips. Staff working for the joint venture between Tesla Inc and Space Exploration Technologies Corp (SpaceX) have sought price quotes and delivery times for an array of chipmaking gear, people familiar with the matter said. In past weeks, they’ve contacted makers of photomasks, substrates, etchers, depositors, cleaning devices, testers and other tools, according to the people, who asked not to
Taichung reported the steepest fall in completed home prices among the six special municipalities in the first quarter of this year, data compiled by Taiwan Realty Co (台灣房屋) showed yesterday. From January through last month, the average transaction price for completed homes in Taichung fell 8 percent from a year earlier to NT$299,000 (US$9,483) per ping (3.3m²), said Taiwan Realty, which compiled the data based on the government’s price registration platform. The decline could be attributed to many home buyers choosing relatively affordable used homes to live in themselves, instead of newly built homes in the city’s prime property market, Taiwan Realty
The government yesterday approved applications by Alphabet Inc’s Google to invest NT$27.08 billion (US$859.98 million) in Taiwan, the Ministry of Economic Affairs said in a statement. The Department of Investment Review approved two investments proposed by Google, with much of the funds to be used for data processing and electronic information supply services, as well as inventory procurement businesses in the semiconductor field, the ministry said. It marks the second consecutive year that Google has applied to increase its investment in Taiwan. Google plans to infuse NT$25.34 billion into Charter Investments Ltd (特許投資顧問) through its Singapore-based subsidiary Fructan Holdings Singapore Pte Ltd, and
JET JUICE: The war on Iran’s secondary effects have seen fuel prices skyrocket, knocking flight schedules down to earth in return as airlines struggle with costs Airline passengers should brace for more irritation in the next few months as carriers worldwide cancel flights and ground planes to cope with stratospheric increases in jet-fuel prices. Dutch flag carrier KLM is the latest company to cut its schedule, saying on Thursday that it would scrap 80 return flights at Amsterdam’s Schiphol Airport in the coming month. That puts it in the same league as United Airlines Holdings Inc, Deutsche Lufthansa AG and Cathay Pacific Airways Ltd, which have all pruned itineraries to mitigate costs. Global capacity for next month has been reduced by about 3 percentage points, with all
RSS